|
Today's Headlines
FDA this week approved integrase strand transfer inhibitor dolutegravir (Tivicay, ViiV Healthcare, GlaxoSmithKline) to treat HIV-1 infection. » Full article
|
|
FDA has approved the first rapid Human Immunodeficiency Virus (HIV) test for the simultaneous detection of HIV-1 p24 antigen as well as antibodies to both HIV-1 and HIV-2 in human serum, plasma, and venous or fingerstick whole blood specimens (The Alere Determine HIV-1/2 Ag/Ab Combo, Orgenics, Ltd. [an Alere, Inc. company]) was approved. » Full article
|
|
Blood pressure response to changes in dietary sodium and potassium is reproducible over the long term and may help identify potential candidates at risk for hypertension and cardiovascular disease, according to a study published in the journal Hypertension. » Full article
|
|
Long-term use of calcium-channel blockers may increase the risk of breast cancer in postmenopausal women, but additional research is needed to confirm, according to a study in JAMA Internal Medicine, published online August 5. » Full article
|
Continuing Education
The fifth Pain Management CPE activity, “Management of common pain medications encountered by pharmacists,” is available. It is the final article in our CPE series: Pain Management Considerations in Medication Therapy Management. Pharmacists can earn up to 10 credits by completing our April 2013 through August 2013 monthly knowledge-based activities.
To read and print the article with TEST QUESTIONS, click here. To proceed to the online exams and earn up to 2 CPE credits, click here to log in.
Announcement: Welcome to the new user registration process. This new process requires all pharmacists and pharmacy technicians to provide
or update their NABP e-Profile ID in order to electronically keep track of CPE credits from ACPE-accredited providers. If you have not done so, you can obtain your NABP e-Profile ID now at
www.MyCPEmonitor.net. This profile will enable you to have one login
for all the NABP programs and services you will need throughout your career.
|
|
EDITOR'S PICK
 Results from a health economic and outcomes research (HECOR) simulation analysis show that canagliflozin (Invokana, Janssen), along with lifestyle management, may reduce long-term complications and associated costs for adult patients with type 2 diabetes compared to a treatment sequence without canagliflozin. » Full article
|
|
|
SURVEY
— Orals will become the most frequently prescribed products
— Injectables will continue to dominate market share
— Equal split between orals and injectables
Click Here to let us know.
|
|
Like
Tweet
